Documents

Displaying 1 - 20 of 206 results
 
Collapse Filters
 
Expand Filters         +
October 12, 2018

Acting Administrator Uttam Dhillon, Instead Opioid Summit Plenary Opening Remarks

Acting Administrator Uttam Dhillon, delivers plenary opening remarks for the Instead Opioid Summit in Salt Lake City Utah

 

October 4, 2018

How to Properly Dispose of Your Unused Medicines

Unused or expired prescription medications are a public safety issue. The Drug Enforcement Administration provides guidance on the right way to dispose of unused medicine.

October 2, 2018

Paul E. Knierim “Stopping the Poison Pills: Combatting the Trafficking of Illegal Fentanyl from China”

Statement before the Caucus on International Narcotics Control United States Senate for a hearing entitled “Stopping the Poison Pills: Combatting the Trafficking of Illegal Fentanyl from China”

September 6, 2018

Paul E. Knierim - Tackling Fentanyl: The China Connection

Statement of Paul E. Knierim Deputy Chief of Operations, Office of Global Enforcement Before the Subcommittee on Africa, Global Health, Global Human Rights and International Organizations Committee on Foreign Affairs U.S. House of Representatives for a hearing entitled "Tackling Fentanyl: The China Connection"

August 13, 2018

Latent Print Examination Manual

Drug Enforcement Administration Office of Forensic Sciences Latent Print Examination Manual July 2018

July 1, 2018

2018 Slang Terms and Code Words

This Drug Enforcement Administration (DEA) Intelligence Report contains new and updated information on slang terms and code words from a variety of law enforcement and open sources, and serves as an updated version to the product entitled “Drug Slang Code Words” published by the DEA in May 2017. It is designed as a ready reference for law enforcement personnel who are confronted with hundreds of slang terms and code words used to identify a wide variety of controlled substances, designer drugs, synthetic compounds, measurements, locations, weapons, and other miscellaneous terms relevant to the drug trade. Although every effort was made to ensure the accuracy and completeness of the information presented, due to the dynamics of the ever-changing drug scene, subsequent additions, deletions, and corrections are inevitable. Future addendums and updates to this report will attempt to capture changed terminology to the furthest extent possible. This compendium of slang terms and code words is alphabetically ordered, with new additions presented in italic text, and identifies drugs and drug categories in English and foreign language derivations. 

June 1, 2018

The Drug Situation in New Jersey (2018)

The Drug Enforcement Administration (DEA) New Jersey Division’s Intelligence Program conducted a bi-annual assessment of the drug threats occurring within the State of New Jersey between January and June 2017. This report highlights the strategic and significant findings regarding the illicit drug trends in the New Jersey Division’s (NJD) area of responsibility (AOR). Unless otherwise noted, data and findings are from DEA reporting. 

May 1, 2018

2018 Fentanyl Remains the Most Significant Synthetic Opioid Threat in US

Fentanyl is the most prevalent and the most significant synthetic opioida threat to the United States and will very likely remain the most prevalent synthetic opioid threat in the near term. The fentanyl threat remains most severe in the white powder heroin user market in the Midwest and Northeast United States, and fentanyl availability continues to be primarily by itself or with heroin. Fentanyl mixtures with non-opioid substances are a cause for public health concern due to the high potential for large numbers of fatal overdoses in short periods of time; however, there is no evidence that transnational criminal organizations (TCO) are trafficking strategic quantities of fentanyl already mixed with non-opioid drugs. Fentanyl’s popularity is unlikely to be challenged in the near term, but traffickers will likely continue to produce new fentanyl-related substances and other novel opioids. 

April 1, 2018

Synthetic Cathinone Sold as Crack Cocaine in Baltimore

In June and July 2017, law enforcement authorities made multiple undercover purchases of crack cocaine from one dealer in Baltimore, MD. In September 2017, official laboratory results indicated that two of these purchases tested as N-ethylpentylone Hydrochloride, a synthetic cathinone (“bath salts”) derivative classified as a Schedule I Controlled Substance Analogue.

April 1, 2018

DEA Data Indicates Cocaine is the Number One Seized Drug in South Carolina

As of October 2017, a review of Drug Enforcement Administration (DEA) National Forensic Laboratory Information System (NFLIS) data show that cocaine submissions indicate it is the number one seized substance by incident by law enforcement officials in South Carolina. The number of submissions has fluctuated with a high of 4,764 (in 2010) and a low of 3,492 (in 2012). The percent of cocaine submissions has declined every year since 2011 when compared to all South Carolina submissions. 

March 30, 2018

Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 79: Security

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 78: Hazardous Waste and Chemical Storage

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 77: Safety

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 76: Laboratory Special Studies

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 75: Laboratory Financial and Resource Management

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 74: Managing Laboratory Stockpiles and Special Programs

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 73: Managing Laboratory Evidence

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 72: Staffing, Training, and Personnel Actions

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of March 30, 2018 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice